Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

Summary

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metastatic Castrate Resistant Prostate Cancer
• BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2
• RAD51B, RAD51C, RAD51D, or RAD54L Mutations

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

Male

Healthy volunteers

Not accepted

Sponsor

VA Office of Research and Development

Last updated on ClinicalTrials.gov

September 17, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites